Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients

Active:	Yes
Cancer Type:	Unknown Primary	NCT ID:	NCT05866302
Trial Phases:		Protocol IDs:	UMCC 2022.052 (primary) NCI-2023-05585 HUM00225273
Eligibility:	36 Months and older, Male and Female	Study Type:	Other
Study Sponsor:	University of Michigan Comprehensive Cancer Center
NCI Full Details:	http://clinicaltrials.gov/show/NCT05866302

Summary

This study is being done to detect and diagnose graft versus host disease (GVHD) of the lungs (termed “lung GVHD”) following a bone marrow or stem cell transplant. Chronic GVHD is a common problem after transplant and if successful, this study may offer patients a new way (called parametric response mapping) to identify lung GVHD.

Objectives

PRIMARY OBJECTIVES:
I. To correlate PRM profiles (PRMfSAD, PRMPD) at the onset of chronic GVHD with subsequent progression to CLD over a 12-month period. (Cohort I)
II. To evaluate PRM as a predictor of “lung function decline” in patients with an established diagnosis of CLD. (Cohort II)

OUTLINE: This is an observational study.

Patients undergo computed tomography (CT), complete pulmonary function tests, and undergo blood sample collection on study. Patients' medical records are reviewed.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.